|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Although the precise function of TM4SF5 remains to be elucidated it may be useful in a clinical setting for tumour diagnosis and/or therapy.
|
9479038 |
1998 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer.
|
9479038 |
1998 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer.
|
9479038 |
1998 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
However, the expression of most of the differential genes, including KIAA1775, was detected by RT-PCR in pituitary or lung tumors, whether secreting ACTH or not, excepted for TM4SF5, which was only detected in some nonendocrine lung tumors.
|
12414866 |
2002 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our observations have revealed a role for TM4SF5 in causing uncontrolled growth of human hepatocarcinoma cells through EMT.
|
18357344 |
2008 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Here, we investigated the role of the tetraspanin transmembrane 4 superfamily member 5 (TM4SF5) in contact inhibition and tumorigenesis.
|
18357344 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We previously reported that the four-transmembrane L6 family member 5 (TM4SF5) was highly expressed in hepatocarcinoma, induced morphological elongation and epithelial-mesenchymal transition, and caused abnormal cell growth in multilayers in vitro and tumor formation in vivo.
|
19177595 |
2009 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, tumors from nude mice injected with TM4SF5-expressing cells and from clinical human hepatocarcinoma tissues showed enhanced integrin alpha(5) expression, vessel formation, and signaling activity, which were inhibited by administration of anti-integrin alpha(5) or -VEGF antibody.
|
19036703 |
2009 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Tumor formation in nude mice injected with TM4SF5-expressing cells and the growth of cells expressing endogenous TM4SF5, but not of TM4SF5-null cells, was suppressed by treatment with TSAHC, but not by treatment with its analogs.
|
19177595 |
2009 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Tetraspan TM4SF5 is highly expressed in a diverse number of tumor types.
|
19036703 |
2009 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, these observations suggest that TSAHC may be a promising anti-tumorigenic reagent, especially against TM4SF5-mediated hepatocarcinoma.
|
21099346 |
2011 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In this study, TSAHC and two derivatives showed similar antagonistic activities against TM4SF5-mediated signaling and multilayer growth in vitro and anti-tumorigenic activity even in early stages of TM4SF5-mediated tumor formation in nude mice.
|
21099346 |
2011 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Meanwhile, sorafenib was only effective much later in tumorigenesis in vivo and affected in vitro proliferation in a TM4SF5-independent manner.
|
21099346 |
2011 |
|
Tumor Angiogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
TM4SF5 is previously shown to mediate tumorigenesis through cytosolic p27Kip1-mediated inactivation of RhoA, epithelial-mesenchymal transition, multilayer growth, migration, invasion, and tumor angiogenesis.
|
21099346 |
2011 |
|
Calcification of coronary artery
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis.
|
22916037 |
2012 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tetraspan TM4SF5-dependent direct activation of FAK and metastatic potential of hepatocarcinoma cells.
|
23077174 |
2012 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that our improved peptide vaccine technology provides a novel prophylaxis measure as well as therapy for HCC patients with TM4SF5-positive tumors.
|
22427965 |
2012 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
These results suggest that our improved peptide vaccine technology provides a novel prophylaxis measure as well as therapy for HCC patients with TM4SF5-positive tumors.
|
22427965 |
2012 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Our findings demonstrate that TM4SF5 directly binds to and activates FAK in an adhesion-dependent manner, to regulate cell migration and invasion, suggesting that TM4SF5 is a promising target in the treatment of metastatic cancer.
|
23077174 |
2012 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Our findings demonstrate that TM4SF5 directly binds to and activates FAK in an adhesion-dependent manner, to regulate cell migration and invasion, suggesting that TM4SF5 is a promising target in the treatment of metastatic cancer.
|
23077174 |
2012 |
|
Disseminated Malignant Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our findings demonstrate that TM4SF5 directly binds to and activates FAK in an adhesion-dependent manner, to regulate cell migration and invasion, suggesting that TM4SF5 is a promising target in the treatment of metastatic cancer.
|
23077174 |
2012 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Our findings demonstrate that TM4SF5 directly binds to and activates FAK in an adhesion-dependent manner, to regulate cell migration and invasion, suggesting that TM4SF5 is a promising target in the treatment of metastatic cancer.
|
23077174 |
2012 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously, we have shown that immunization with TM4SF5 peptide-CpG-DNA-liposome complex induces production of TM4SF5-specific antibodies and protects mice from HCC progression in an allograft model.
|
23624388 |
2013 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Wildtype (WT) TM4SF5 expression enhanced migration and invasive protrusion formation in a c-Src-dependent manner, compared with TM4SF5-null control hepatoma cell lines.
|
23220047 |
2013 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Robust production of TM4SF5-specific antibodies was induced by challenge with CT-26 cells and the tumor growth was significantly suppressed in the immunized mice.
|
23624388 |
2013 |